Which has better earnings & valuation, LFMD or NAKA?

LifeMD has higher revenue and earnings than KindlyMD. KindlyMD is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 1.21 $14.35M $0.05 97.40 KindlyMD $1.82M 36.90 -$52.23M -$43.20 N/A

Is LFMD or NAKA more profitable?

LifeMD has a net margin of 2.37% compared to KindlyMD's net margin of -7,397.12%. KindlyMD's return on equity of -81.32% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% KindlyMD -7,397.12% -81.32% -54.17%

Which has higher earnings and valuation, BDSX or NAKA?

Biodesix has higher revenue and earnings than KindlyMD. Biodesix is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 2.57 -$35.26M -$4.06 N/A KindlyMD $1.82M 36.90 -$52.23M -$43.20 N/A

Is BDSX or NAKA more profitable?

Biodesix has a net margin of -33.26% compared to KindlyMD's net margin of -7,397.12%. KindlyMD's return on equity of -81.32% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -33.26% -2,101.40% -35.65% KindlyMD -7,397.12% -81.32% -54.17%

Which has higher earnings & valuation, NAKA or XGN?

Exagen has higher revenue and earnings than KindlyMD. Exagen is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KindlyMD $1.82M 36.90 -$52.23M -$43.20 N/A Exagen $66.57M 1.65 -$19.95M -$0.89 N/A

Is NAKA or XGN more profitable?

Exagen has a net margin of -29.49% compared to KindlyMD's net margin of -7,397.12%. KindlyMD's return on equity of -81.32% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets KindlyMD -7,397.12% -81.32% -54.17% Exagen -29.49% -94.37% -28.96%

Do analysts recommend NAKA or BNR?

KindlyMD presently has a consensus target price of $30.00, suggesting a potential upside of 677.20%. Given KindlyMD's stronger consensus rating and higher probable upside, research analysts clearly believe KindlyMD is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KindlyMD 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to NAKA or BNR?

In the previous week, Burning Rock Biotech had 15 more articles in the media than KindlyMD. MarketBeat recorded 16 mentions for Burning Rock Biotech and 1 mentions for KindlyMD. Burning Rock Biotech's average media sentiment score of 1.01 beat KindlyMD's score of 0.00 indicating that Burning Rock Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KindlyMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Burning Rock Biotech 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

KindlyMD (NAKA) Competitors

$3.86 0.00 (0.00%)

As of 07/2/2026 04:00 PM Eastern

Compare

NAKA vs. LFMD, BDSX, XGN, BNR, and PARK

Should you buy KindlyMD stock or one of its competitors? MarketBeat compares KindlyMD with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with KindlyMD include LifeMD (LFMD), Biodesix (BDSX), Exagen (XGN), Burning Rock Biotech (BNR), and Park Dental Partners (PARK). These companies are all part of the "healthcare" industry.

How does KindlyMD compare to LifeMD?

LifeMD (NASDAQ:LFMD) and KindlyMD (NASDAQ:NAKA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

LifeMD has higher revenue and earnings than KindlyMD. KindlyMD is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.21	$14.35M	$0.05	97.40
KindlyMD	$1.82M	36.90	-$52.23M	-$43.20	N/A

LifeMD has a net margin of 2.37% compared to KindlyMD's net margin of -7,397.12%. KindlyMD's return on equity of -81.32% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
KindlyMD	-7,397.12%	-81.32%	-54.17%

LifeMD has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market. Comparatively, KindlyMD has a beta of 16.05, meaning that its stock price is 1,505% more volatile than the broader market.

In the previous week, KindlyMD had 1 more articles in the media than LifeMD. MarketBeat recorded 1 mentions for KindlyMD and 0 mentions for LifeMD. LifeMD's average media sentiment score of 0.00 equaled KindlyMD'saverage media sentiment score.

Company	Overall Sentiment
LifeMD	Neutral
KindlyMD	Neutral

LifeMD currently has a consensus target price of $9.14, suggesting a potential upside of 87.74%. KindlyMD has a consensus target price of $30.00, suggesting a potential upside of 677.20%. Given KindlyMD's higher probable upside, analysts clearly believe KindlyMD is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

35.5% of LifeMD shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 24.5% of KindlyMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

LifeMD beats KindlyMD on 9 of the 15 factors compared between the two stocks.

How does KindlyMD compare to Biodesix?

Biodesix (NASDAQ:BDSX) and KindlyMD (NASDAQ:NAKA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

In the previous week, KindlyMD had 1 more articles in the media than Biodesix. MarketBeat recorded 1 mentions for KindlyMD and 0 mentions for Biodesix. Biodesix's average media sentiment score of 0.00 equaled KindlyMD'saverage media sentiment score.

Company	Overall Sentiment
Biodesix	Neutral
KindlyMD	Neutral

Biodesix has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, KindlyMD has a beta of 16.05, indicating that its share price is 1,505% more volatile than the broader market.

21.0% of Biodesix shares are owned by institutional investors. 23.2% of Biodesix shares are owned by insiders. Comparatively, 24.5% of KindlyMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Biodesix has higher revenue and earnings than KindlyMD. Biodesix is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	2.57	-$35.26M	-$4.06	N/A
KindlyMD	$1.82M	36.90	-$52.23M	-$43.20	N/A

Biodesix has a net margin of -33.26% compared to KindlyMD's net margin of -7,397.12%. KindlyMD's return on equity of -81.32% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
KindlyMD	-7,397.12%	-81.32%	-54.17%

Biodesix currently has a consensus target price of $28.33, suggesting a potential upside of 28.85%. KindlyMD has a consensus target price of $30.00, suggesting a potential upside of 677.20%. Given KindlyMD's higher probable upside, analysts clearly believe KindlyMD is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Biodesix beats KindlyMD on 8 of the 15 factors compared between the two stocks.

How does KindlyMD compare to Exagen?

KindlyMD (NASDAQ:NAKA) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

KindlyMD has a beta of 16.05, meaning that its share price is 1,505% more volatile than the broader market. Comparatively, Exagen has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

Exagen has a net margin of -29.49% compared to KindlyMD's net margin of -7,397.12%. KindlyMD's return on equity of -81.32% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KindlyMD	-7,397.12%	-81.32%	-54.17%
Exagen	-29.49%	-94.37%	-28.96%

75.3% of Exagen shares are owned by institutional investors. 24.5% of KindlyMD shares are owned by insiders. Comparatively, 10.4% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, KindlyMD had 1 more articles in the media than Exagen. MarketBeat recorded 1 mentions for KindlyMD and 0 mentions for Exagen. KindlyMD's average media sentiment score of 0.00 equaled Exagen'saverage media sentiment score.

Company	Overall Sentiment
KindlyMD	Neutral
Exagen	Neutral

KindlyMD presently has a consensus target price of $30.00, suggesting a potential upside of 677.20%. Exagen has a consensus target price of $9.11, suggesting a potential upside of 100.69%. Given KindlyMD's higher possible upside, equities analysts plainly believe KindlyMD is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Exagen has higher revenue and earnings than KindlyMD. Exagen is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KindlyMD	$1.82M	36.90	-$52.23M	-$43.20	N/A
Exagen	$66.57M	1.65	-$19.95M	-$0.89	N/A

Summary

Exagen beats KindlyMD on 9 of the 16 factors compared between the two stocks.

How does KindlyMD compare to Burning Rock Biotech?

KindlyMD (NASDAQ:NAKA) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

In the previous week, Burning Rock Biotech had 15 more articles in the media than KindlyMD. MarketBeat recorded 16 mentions for Burning Rock Biotech and 1 mentions for KindlyMD. Burning Rock Biotech's average media sentiment score of 1.01 beat KindlyMD's score of 0.00 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KindlyMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Burning Rock Biotech	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

30.0% of Burning Rock Biotech shares are held by institutional investors. 24.5% of KindlyMD shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

KindlyMD has a beta of 16.05, indicating that its share price is 1,505% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Burning Rock Biotech has higher revenue and earnings than KindlyMD. Burning Rock Biotech is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KindlyMD	$1.82M	36.90	-$52.23M	-$43.20	N/A
Burning Rock Biotech	$77.16M	1.34	-$7.92M	-$0.82	N/A

Burning Rock Biotech has a net margin of -11.57% compared to KindlyMD's net margin of -7,397.12%. Burning Rock Biotech's return on equity of -10.98% beat KindlyMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KindlyMD	-7,397.12%	-81.32%	-54.17%
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

KindlyMD presently has a consensus target price of $30.00, suggesting a potential upside of 677.20%. Given KindlyMD's stronger consensus rating and higher probable upside, research analysts clearly believe KindlyMD is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Burning Rock Biotech beats KindlyMD on 10 of the 16 factors compared between the two stocks.

How does KindlyMD compare to Park Dental Partners?

KindlyMD (NASDAQ:NAKA) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Park Dental Partners has a net margin of 0.00% compared to KindlyMD's net margin of -7,397.12%. Park Dental Partners' return on equity of 0.00% beat KindlyMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KindlyMD	-7,397.12%	-81.32%	-54.17%
Park Dental Partners	N/A	N/A	N/A

In the previous week, KindlyMD had 1 more articles in the media than Park Dental Partners. MarketBeat recorded 1 mentions for KindlyMD and 0 mentions for Park Dental Partners. KindlyMD's average media sentiment score of 0.00 equaled Park Dental Partners'average media sentiment score.

Company	Overall Sentiment
KindlyMD	Neutral
Park Dental Partners	Neutral

Park Dental Partners has higher revenue and earnings than KindlyMD. KindlyMD is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KindlyMD	$1.82M	36.90	-$52.23M	-$43.20	N/A
Park Dental Partners	$248.15M	0.38	-$360K	$0.74	28.26

KindlyMD presently has a consensus target price of $30.00, indicating a potential upside of 677.20%. Park Dental Partners has a consensus target price of $21.75, indicating a potential upside of 4.02%. Given KindlyMD's higher possible upside, equities analysts clearly believe KindlyMD is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

Summary

Park Dental Partners beats KindlyMD on 9 of the 13 factors compared between the two stocks.

Get KindlyMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAKA vs. The Competition

Export

Metric	KindlyMD	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$67.17M	$9.63B	$7.16B	$12.48B
Dividend Yield	N/A	1.62%	2.66%	6.52%
P/E Ratio	-0.09	27.84	28.02	24.70
Price / Sales	36.90	18.50	540.37	99.46
Price / Cash	N/A	114.69	49.26	57.09
Price / Book	0.08	6.19	10.96	6.46
Net Income	-$52.23M	$179.69M	$3.57B	$337.01M
7 Day Performance	0.52%	3.82%	2.12%	1.69%
1 Month Performance	-10.44%	10.36%	5.25%	3.81%
1 Year Performance	-99.24%	14.53%	33.29%	23.90%

KindlyMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAKA KindlyMD	3.4756 of 5 stars	$3.86 flat	$30.00 +677.2%	-99.2%	$67.17M	$1.82M	N/A	N/A	Gap Up
LFMD LifeMD	2.2745 of 5 stars	$4.44 -2.5%	$9.14 +106.2%	-61.2%	$215.46M	$193.33M	89.12	230
BDSX Biodesix	3.4706 of 5 stars	$18.93 -1.2%	$26.50 +40.0%	+298.4%	$196.04M	$96.10M	N/A	220	Gap Up
XGN Exagen	3.6425 of 5 stars	$4.44 +1.8%	$9.25 +108.3%	-32.6%	$107.44M	$68.38M	N/A	220	Gap Up
BNR Burning Rock Biotech	1.8318 of 5 stars	$8.39 +11.0%	N/A	+191.0%	$88.26M	$77.16M	N/A	1,390	News Coverage Insider Trade Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAKA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

KindlyMD (NAKA) Competitors